The Current State of CFTR Modification

Volume 6, Issue 2.

In this issue we are joined by one of our Program Directors, Dr. Noah Lechtzin from the Johns Hopkins University. Dr. Lechtzin will address the current state of CFTR modification and how it can be applied in practice.

Take our post-test to claim CME credits:
Physician post-test
Nurse post-test

To read a companion newsletter click here.

Breaking Coverage of CAT trial

Special Edition 2015, Part 4.

Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Stuart Elborn of Queen’s University in Belfast, Ireland. Dr. Elborn discusses the implications of the CAT study and how it effects his practice.

Breaking Coverage of CAT trial

Special Edition 2015, Part 3.

Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. JP Clancy of Cincinnati Children’s Hospital. Dr. Clancy discusses the implications of the CAT study and how it effect his practice.

Breaking Coverage of CAT trial

Special Edition 2015, Part 2.

Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Scott Bell of the QIMR Berghofer Medical Research Institute. Dr. Bell discusses the implications of the CAT study and how it will effect his practice.

Breaking Coverage of CAT trial

Special Edition 2015, Part 1.

Join us as Dr. Peter Mogayzel of the Johns Hopkins University discusses the design and findings for the CAT study with Dr. Patrick Flume of the Medical University of South Carolina. Learn about the importance of the study and how it may effect your practice.

Agents for the management of Pseudomonas aeruginosa infection

Volume 5, Issue 14.

In this issue we are joined by Dr. Shawn Aaron of University of Ottawa in Ontario, Canada. Dr. Aaron will discuss infection in patients with optimal therapy of chronic Pseudomonas aeruginosa cystic fibrosis, describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibrosis, and evaluate the optimal choice of antibiotics to treat Pseudomonas-associated pulmonary exacerbations in patients with cystic fibrosis.

Benefits of CFTR Modification Beyond FEV1 Improvement

Volume 5, Issue 12.

In this issue of eCysticfibrosis Review Dr. Chris Goss of the University of Washington Medical Center. Dr. Goss discusses the benefits of CFTR modification beyond Fev1 improvement through the use of patient-cases.

The Effects of CFTR-modifying Therapies

Volume 5, Issue 10.

In this issue of eCystifibrosis Review we will be join by Dr. Stuart Elborn of Queens University in Belfast, Northern Ireland. Dr. Elborn discusses the effects of CFTR-Modifying Therapies. He will present three patient-case scenarios and identify appropriate treatment options.

Optimizing Nutrition in Individuals with Cystic Fibrosis

Volume 5, Issue 8.

In this issue of eCysticFibrosis Review Dr. John Pohl discuses how to optimize nutrition in individuals with CF. Through patient case-scenarios he applies best practices to achieve optimal nutrition using PERT dosing.

Improving digestive capabilities in nutritionally compromised patients with CF

Volume 5, Issue 6.

In this issue Dr. Steven Freedman, Professor of Medicine from Harvard Medical School discusses digestive capabilities in nutritionally compromised patients with CF. Listen in as Dr. Freedman explains the importance of pancreatic enzyme replacement and present patient scenarios and best practices of treatment.